First cases of infection with the 21L/BA.2 Omicron variant in Marseille, France.
Omicron
SARS-CoV-2
emergence
southern France
travel
variant
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
28
02
2022
received:
08
02
2022
accepted:
01
03
2022
pubmed:
5
3
2022
medline:
21
5
2022
entrez:
4
3
2022
Statut:
ppublish
Résumé
The SARS-CoV-2 21K/BA.1, 21L/BA.2, and BA.3 Omicron variants have recently emerged worldwide. To date, the 21L/BA.2 Omicron variant has remained very minority globally but became predominant in Denmark instead of the 21K/BA.1 variant. Here, we describe the first cases diagnosed with this variant in south-eastern France. We identified 13 cases using variant-specific qPCR and next-generation sequencing between 28/11/2021 and 31/01/2022, the first two cases being diagnosed in travelers returning from Tanzania. Overall, viral genomes displayed a mean (±standard deviation) number of 65.9 ± 2.5 (range, 61-69) nucleotide substitutions and 31.0 ± 8.3 (27-50) nucleotide deletions, resulting in 49.6 ± 2.2 (45-52) amino acid substitutions (including 28 in the spike protein) and 12.4 ± 1.1 (12-15) amino acid deletions. Phylogeny showed the distribution in three different clusters of these genomes, which were most closely related to genomes from England and South Africa, from Singapore and Nepal, or from France and Denmark. Structural predictions highlighted a significant enlargement and flattening of the surface of the 21L/BA.2 N-terminal domain of the spike protein compared to that of the 21K/BA.1 Omicron variant, which may facilitate initial viral interactions with lipid rafts. Close surveillance is needed at global, country, and center scales to monitor the incidence and clinical outcome of the 21L/BA.2 Omicron variant.
Identifiants
pubmed: 35243660
doi: 10.1002/jmv.27695
pmc: PMC9088623
doi:
Substances chimiques
Nucleotides
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3421-3430Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Nature. 2021 Jul;595(7869):713-717
pubmed: 34192736
Nature. 2022 Feb;602(7895):26-28
pubmed: 35091701
J Med Virol. 2022 May;94(5):2019-2025
pubmed: 34997962
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Arch Virol. 2022 Apr;167(4):1185-1190
pubmed: 35178586
J Med Virol. 2022 Jun;94(6):2360-2364
pubmed: 35150013
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
Nature. 2021 Dec;600(7889):408-418
pubmed: 34880490
Front Microbiol. 2022 Feb 07;12:786233
pubmed: 35197938
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
J Infect. 2021 Aug;83(2):197-206
pubmed: 34089757
Euro Surveill. 2021 Dec;26(50):
pubmed: 34915977
Nature. 2022 Feb;602(7898):657-663
pubmed: 35016194
Euro Surveill. 2020 Aug;25(32):
pubmed: 32794443
J Med Virol. 2022 May;94(5):1808-1810
pubmed: 35043399
J Med Virol. 2022 May;94(5):2290-2295
pubmed: 35060146
Mol Biol Evol. 2021 Jan 23;38(2):702-715
pubmed: 32941612
J Med Virol. 2022 Jul;94(7):3421-3430
pubmed: 35243660